ACHIEVE Pilot Statins for Vascular Protection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

225 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-19

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ACHIEVE aims to increase statin usage among patients with ASCVD by having a pharmacist talk to patients and providers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome

NCT00728988

Acute Coronary Syndrome

COMPLETED PHASE4

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348

Acute Myocardial Infarction

COMPLETED PHASE4

Postprandial Lipemia and Endothelial Function in ACCORD- Ancillary to ACCORD

NCT00037401

Atherosclerosis Cardiovascular Diseases Hypercholesterolemia +1 more

COMPLETED

Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery

NCT01186289

Neurocognitive Dysfunction

WITHDRAWN NA

Study of Atorvastatin Dose Dependent Reduction of Proteinuria

NCT00768638

Chronic Kidney Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States (U.S.) Statins reduce the risk of cardiovascular events by 30% in those with prior history of ASCVD. Despite being inexpensive and well-tolerated, however, statins are underused in clinical practice, particularly in patients who identify as Black. A large-scale intervention to improve evidence-based statin initiation among individuals with ASCVD is needed, particularly for the Black population. To meet this need, we aim to conduct a multi-center, pragmatic, cluster randomized, controlled trial to assess the impact of a provider- and patient-directed intervention to increase the prescription of, and adherence to, appropriate statin therapy among those with ASCVD (ACHIEVE: A Controlled trial to improve use of High IntEnsity statins for Vascular protEction). The intervention will be pharmacist-led, embedded in commercial payer systems, partnering with the National Committee for Quality Assurance (NCQA), and with a particular emphasis on improving statin use in the Black population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ASCVD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No statin

Patients who are identified with ASCVD who do not take a statin or do not take the recommended dose.

Pharmacist call

Intervention Type OTHER

Pharmacists will call patients and their providers to discuss benefits of statin use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist call

Pharmacists will call patients and their providers to discuss benefits of statin use

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of atherosclerotic cardiovascular disease currently not treated with a moderate- high intensity statin and the providers that care for them.
* Patient age 18-75